| 0.2869 0.002 (0.53%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.35 | 1-year : | 0.39 |
| Resists | First : | 0.3 | Second : | 0.33 |
| Pivot price | 0.29  |
|||
| Supports | First : | 0.24 | Second : | 0.2 |
| MAs | MA(5) : | 0.28  |
MA(20) : | 0.28 |
| MA(100) : | 0.34 |
MA(250) : | 0.38 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 42.7 |
D(3) : | 44.8 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 0.73 | Low : | 0.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CYBN ] has closed above bottom band by 42.2%. Bollinger Bands are 6.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.29 - 0.29 | 0.29 - 0.29 |
| Low: | 0.28 - 0.28 | 0.28 - 0.28 |
| Close: | 0.28 - 0.29 | 0.29 - 0.29 |
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Sat, 20 Jul 2024
Cybin (OTCMKTS:CYBN) Stock Price Down 1.8% - American Banking and Market News
Wed, 10 Jul 2024
The Globe and Mail - The Globe and Mail
Mon, 08 Jul 2024
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update - StockTitan
Thu, 27 Jun 2024
What Makes Cybin Inc. (CYBN) a New Buy Stock - Yahoo Finance
Tue, 11 Jun 2024
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround - Yahoo Finance
Wed, 05 Jun 2024
Psychedelic-medicine stocks drop after ecstasy's rocky day at the FDA - Morningstar
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 406 (M) |
| Shares Float | 352 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 6.8 (%) |
| Shares Short | 12,400 (K) |
| Shares Short P.Month | 10,770 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.7 % |
| Return on Equity (ttm) | -90.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -1.6 |
| PEG Ratio | 0 |
| Price to Book value | 1.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|